Multiple key product opportunities have been identified by Amneal across small-molecule generics, complex generics and biosimilars, as the firm looks to maintain momentum that saw it deliver double-digit growth in revenues and adjusted EBITDA in the first three months of 2023.
Matching earlier Q1 previews based on preliminary financials (see sidebar), Amneal saw net revenue grow by 12% to $558m and...








